Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Exclusive Article
This 4/20, Wall Street Is Betting on More Than MarijuanaSubmitted by Jeffrey Neal Johnson. Article Published: 4/20/2026. 
Key Points
- A new executive order fast-tracking psychedelic medicines triggered single-session gains of roughly 40% for Compass Pathways and over 20% for Atai Beckley.
- The cannabis sector has shifted away from speculative policy bets, with Curaleaf and Innovative Industrial Properties rewarding shareholders through buybacks and dividends.
- A barbell strategy pairing high-growth psychedelic stocks against cash-generating cannabis operators could help balance risk and return in the alternative medicine space.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
While many investors focused on the annual 4/20 holiday, expecting the usual buzz around marijuana stocks, a quiet revolution was unfolding in Washington. Over a weekend when most markets were closed, the administration issued a bombshell executive order designed to fast-track psychedelic medicines to market. This single catalyst has effectively split the alternative drug sector in two. It has created a powerful new dynamic that separates high-octane growth opportunities from mature, value-oriented plays, leaving unprepared investors navigating a suddenly transformed landscape.
The "Sucker's Bet" Most New Options Traders Fall For
Most people who try options lose money the same way.
They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter.
Normally $29.97. Free today. Download your copy now.
The market used to treat this entire space as one big, speculative bet on drug reform. That playbook is now obsolete. Today, a clear, bifurcated strategy has emerged for those looking to capitalize on the future of alternative medicine. From Trials to Takeoff: The FDA Fast-Track Ignites a RallyThe market’s reaction to the weekend news was immediate and forceful. Compass Pathways PLC (NASDAQ: CMPS), a leader in psilocybin therapy research, saw its stock jump roughly 40% in a single session. Similarly, Atai Beckley (NASDAQ: ATAI), which develops a diverse portfolio of mental health treatments, rose by more than 20%. These explosive moves were amplified by a classic short-squeeze dynamic. Prior to the announcement, many institutional investors were betting against these stocks, borrowing shares to sell them in the hopes of buying them back later at a lower price. Short interest in Compass Pathways, for instance, had reached nearly 10% of its public float. The unexpected news forced short sellers to buy back shares and close their losing positions, and that rush of buying pushed the stock price sharply higher. Atai Beckley had a similar short interest of about 9.2%, suggesting it too may have been ripe for a short squeeze. For investors, the administration's new policy directly addresses the primary risk inherent in biotechnology: cash burn. Clinical trials are long and expensive. By creating a fast-track to commercialization, the government is effectively shortening the time these companies must spend burning through capital before generating revenue. This shift fundamentally de-risks the path to profitability by reducing the need for future dilutive financing and accelerating the timeline to potential positive cash flow. The bull case is that with this regulatory tailwind, the conversation shifts from whether these companies can get their treatments to market to how quickly. The next 12 to 18 months could see companies like Compass and Atai accelerate their New Drug Application (NDA) submissions to the Food and Drug Administration. An NDA is the formal step a drug sponsor takes to request that the FDA consider approving a new drug for marketing and sale. Securing an expedited review puts these companies on a direct course to commercial partnerships and to tapping into a multi-billion-dollar mental health market targeting conditions like treatment-resistant depression and PTSD. Still, investors should remain aware that these are pre-revenue companies, and their ultimate success remains tied to positive clinical outcomes and successful commercial execution. Cannabis Grows Up: The New Focus on Profits, Not PolicyWhile psychedelic stocks were launching, the legacy cannabis sector experienced a much more subdued 4/20. The AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS), a broad gauge of the industry, saw only a modest bump. This muted reaction signals a critical evolution: the sector no longer trades solely on speculative legalization hype. Instead, the market is now rewarding tangible business fundamentals and shareholder returns. The real story in cannabis lies with the operators generating significant cash for investors. Consider these signs of corporate maturity:
Curaleaf Holdings (OTCMKTS: CURLF), a global revenue leader that generated over $333 million in its most recent quarter, announced a substantial share buyback program. For investors, a buyback signals management's confidence in the stock's valuation and reduces the number of shares outstanding, which can increase earnings per share. Innovative Industrial Properties (NYSE: IIPR) operates as a real estate investment trust (REIT). IIPR is essentially a landlord for licensed cannabis operators: it buys properties and leases them to growers, a model that insulates it from the volatility of plant-touching businesses. This strategy has proven profitable, allowing the company to generate over $111 million in profit and reward shareholders with a hefty 14% dividend yield. The primary risk for cannabis investors has long been the slow pace of federal policy reform. However, companies like Curaleaf and IIPR are mitigating this risk by creating shareholder value today. Looking ahead, the administration's favorable stance on alternative medicines suggests the next logical catalysts are federal descheduling and the passage of banking reform that fully integrates cannabis businesses into the financial system. Such legislation would clear the path for industry giants like Curaleaf to uplist from the over-the-counter (OTC) markets to major U.S. exchanges, such as NASDAQ. An uplisting is a major validation that dramatically increases a stock's liquidity and opens it to a much larger pool of institutional investors and mutual funds. Balancing the Buzz: A Strategy for Psychedelics and CannabisThe alternative drug market now presents two distinct and compelling paths. The weekend’s policy shockwave has supercharged the psychedelic sector, creating an explosive, policy-driven growth opportunity. This stands in sharp contrast to the cannabis sector, where industry leaders have graduated into mature value plays focused on generating cash and rewarding shareholders. This bifurcation lends itself to a barbell strategy: concentrate a portfolio on two extremes — high-growth speculation and stable value — with little in the middle. The high-growth potential of psychedelic stocks like Compass and Atai Beckley represents one side of the barbell. The other is anchored by the stability and cash flow of established cannabis operators like Curaleaf Holdings and Innovative Industrial Properties. Ultimately, how an investor approaches this new landscape will depend on their individual strategy and risk tolerance. Those with a higher tolerance for risk and a focus on growth may find the policy-driven momentum in the psychedelic space compelling. Meanwhile, investors seeking value, income, and tangible fundamentals may gravitate toward established cannabis companies that are already demonstrating solid profitability. |
0 Response to "We're excited to have you on board"
Post a Comment